Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET

Clinical Nuclear Medicine

Volumn 34, Issue 7, 2009, Pages 417-420

  Huyge, Valérie ^a   Garcia, Camilo ^a   Vanderstappen, Anja ^a   Alexiou, Jean ^a   Gil, Thierry ^a   Flamen, Patrick ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bone metastases; Breast cancer; Positron emission tomography (PET)

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; CA 15-3 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FALSE NEGATIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; OSTEOPOROSIS; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY SCINTISCANNING;

EID: 67650637694     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181a7d03c     Document Type: Article

References (12)

1. Israel O, Goldberg A, Nachtigal A, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur JNucl Med Mol Imaging. 2006;33:1280-1284.
2. Du Y, Cullum I, Illidge TM, et al. Fusion of metabolic function and morphology: sequential [18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440-3447.
3. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-3379.
4. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol. 2005;184:1266-1273.
5. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253-1258.
6. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.
7. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135-142.
8. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953.
9. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med. 1999;29:69-79.
10. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintig-raphy alone and nonfused scintigraphy and CT. Radiology. 2006;238: 264-271.
11. Römer W, Nömayr A, Uder M, et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47:1102-1106.
12. Strobel K, Burger C, Seifert B, et al. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol. 2007;188:W467- W474.